NEW YORK, NY--(Marketwire -07\/24\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on AEterna Zentaris Inc. (AEZS) (AEZ.TO) and MannKind Corporation (MNKD). <\/p>\n
Access to the full company reports can be found at: <\/p>\n
http:\/\/www.ParagonReport.com\/AEZS<\/a> http:\/\/www.ParagonReport.com\/MNKD<\/a> <\/p>\n Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.ParagonReport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The company last month reported its Japanese partner Yakult Honsha has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine. <\/p>\n MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Their lead investigational product candidate, AFREZZA is a novel, ultra rapid-acting mealtime insulin therapy. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Link: NEW YORK, NY--(Marketwire -07\/24\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. Continue reading
\nDespite Navigating More Challenging Regulation Process Biotech Companies Thriving in 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"